Adam Levy

Adam Levy

Director of Finance/CFO at ACRIVON THERAPEUTICS, INC.

Net worth: 107 440 $ as of 31/05/2026

60 year
Health Technology
Consumer Services

Profile

Adam D.
Levy
is currently Director at Vesselon, Inc. and will be Chief Financial Officer at Acrivon Therapeutics, Inc. starting in 2025.
Former roles include Executive Director-Investor Relations at Gilead Sciences, Inc. from 2016 to 2020, EVP-Corporate Development & Investor Relations at Alaunos Therapeutics, Inc. in 2021, Senior VP-Communications & Investor Relations at Turning Point Therapeutics, Inc. from 2021 to 2022, and Senior Vice President-Investor Relations at Zentalis Pharmaceuticals, Inc. from 2022 to 2023.
Education includes an MBA from Kellogg School of Management and undergraduate studies at the University of Illinois At Urbana–Champaign.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
18/05/2026 67,150 ( 0.16% ) 107 440 $ 31/05/2026

Adam Levy active positions

CompaniesPositionStart
ACRIVON THERAPEUTICS, INC. Director of Finance/CFO 01/04/2025
Director/Board Member -

Former positions of Adam Levy

CompaniesPositionEnd
ZENTALIS PHARMACEUTICALS, INC. Investor Relations Contact 01/01/2023
TURG POIN Investor Relations Contact 01/01/2022
ALAUNOS THERAPEUTICS, INC. Investor Relations Contact 31/12/2021
GILEAD SCIENCES, INC. Corporate Officer/Principal 01/01/2020
See the detail of Adam Levy's experience

Training of Adam Levy

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

32

1st degree connections

9

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies9

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Consumer Services

Consumer Services

Health Technology

Health Technology